Chen ZK, Zhao JW, Meng WY, Wang YG. Peroxiredoxin 1 as a novel pyroptosis inducer in colorectal cancer: Insights and future directions. World J Gastroenterol 2026; 32(8): 116016 [DOI: 10.3748/wjg.v32.i8.116016]
Corresponding Author of This Article
Yu-Gang Wang, MD, Chief Physician, Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Shanghai 200336, China. wang_yugang@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Feb 28, 2026 (publication date) through Feb 14, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Chen ZK, Zhao JW, Meng WY, Wang YG. Peroxiredoxin 1 as a novel pyroptosis inducer in colorectal cancer: Insights and future directions. World J Gastroenterol 2026; 32(8): 116016 [DOI: 10.3748/wjg.v32.i8.116016]
World J Gastroenterol. Feb 28, 2026; 32(8): 116016 Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.116016
Peroxiredoxin 1 as a novel pyroptosis inducer in colorectal cancer: Insights and future directions
Zi-Ke Chen, Jia-Wei Zhao, Wen-Ying Meng, Yu-Gang Wang
Zi-Ke Chen, Jia-Wei Zhao, Wen-Ying Meng, Yu-Gang Wang, Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China
Zi-Ke Chen, Jia-Wei Zhao, Yu-Gang Wang, Hongqiao International Institute of Medicine, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China
Zi-Ke Chen, Jia-Wei Zhao, Wen-Ying Meng, Yu-Gang Wang, Key Laboratory for Translational Research and Innovative Therapeutics of Gastrointestinal Oncology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China
Co-first authors: Zi-Ke Chen and Jia-Wei Zhao.
Co-corresponding authors: Wen-Ying Meng and Yu-Gang Wang.
Author contributions: Chen ZK and Zhao JW wrote the original draft and are co-first authors; Meng WY and Wang YG edited and reviewed the content and are co-corresponding authors; all authors approved the final version to publish.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Yu-Gang Wang, MD, Chief Physician, Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Shanghai 200336, China. wang_yugang@sina.com
Received: October 31, 2025 Revised: December 6, 2025 Accepted: December 24, 2025 Published online: February 28, 2026 Processing time: 103 Days and 14.8 Hours
Abstract
This letter aims to comment on the paper by He et al, which investigated the role and mechanism of peroxiredoxin 1 (Prdx1) in colorectal cancer (CRC). In the original study, Prdx1 messenger RNA and protein levels were significantly increased in 60 clinical samples from CRC patients, in vitro cell experiments (RKO, SW480, HCT116 cells) and subcutaneous xenograft tumor mouse model. Recombinant Prdx1 (rPrdx1) inhibited the malignant behavior of RKO and SW480 cells, which was mechanistically shown to activate the NOD-like receptor thermal protein domain associated protein 3/caspase-1/gasdermin D (GSDMD) pathway to induce pyroptosis. Consequently, this pyroptosis-based anti-tumor activity effectively inhibited the growth of CRC xenografts in mice. We commend the study’s scientific validity and innovation, the findings of which warrant further investigation into clinical translation, such as developing Prdx1/GSDMD co-expression markers and exploring rPrdx1-based combination therapies for advancing individualized CRC treatment.
Core Tip: Pyroptosis is a key link of “cell death-anti-tumor immunity” in colon cancer, which not only directly suppresses tumor through gasdermin D-mediated cell lysis, but also releases inflammatory factors to remodel the immune microenvironment. In the future, advancing targeted pyroptosis strategies toward molecular intervention, deepening mechanistic insights, and validating multi-dimensional approaches will be crucial to address current challenges and improve outcomes in colon cancer treatment.
